Get the Stockscreener App
14.25
1.42%
0.20
After Hours:
14.45
0.20
+1.40%
Delcath Systems Inc stock is traded at $14.25, with a volume of 384.96K.
It is up +1.42% in the last 24 hours and down -10.94% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
See More
Previous Close:
$14.05
Open:
$13.97
24h Volume:
384.96K
Relative Volume:
0.98
Market Cap:
$515.85M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-5.0532
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
-12.95%
1M Performance:
-10.94%
6M Performance:
+77.90%
1Y Performance:
+229.86%
1-Day Range:
$13.43
$14.36
1-Week Range:
$13.43
$16.34
52-Week Range:
$3.70
$16.97
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
14.25 | 515.85M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
135.82 | 235.56B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
390.30 | 148.93B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
100.72 | 148.64B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
90.48 | 116.11B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.45 | 42.14B | 5.72B | 4.17B | 490.10M | 6.97 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Painful week for retail investors invested in Delcath Systems, Inc. (NASDAQ:DCTH) after 14% drop, institutions also suffered losses - Simply Wall St
Where are the Opportunities in (DCTH) - Stock Traders Daily
Liver Cancer Treatment Pioneer Delcath Reports Q4 Earnings: Will Growth Continue? - StockTitan
Intrahepatic Cholangiocarcinoma Market: Analysis - openPR
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength - Nasdaq
Delcath Systems Announces Update To National Comprehensive Cancer Network Clinical Practice Guidelines - Marketscreener.com
Delcath Systems Announces Update to National Comprehensive Cance - WICZ
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy - StockTitan
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice - MSN
(DCTH) Proactive Strategies - Stock Traders Daily
Delcath Delivers 100% Gain In Less Than 6 Months - RTTNews
Analysts Say Delcath Systems Inc Can Reach $22 In 12 Months - Marketing Sentinel
Delcath Systems: Strong Position In Metastatic Uveal Melanoma, But Broader Growth Challenges Ahead - Seeking Alpha
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet - Nasdaq
How should investors view Delcath Systems Inc (DCTH)? - US Post News
Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc. - AOL
16,978 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Baader Bank Aktiengesellschaft - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update - MarketBeat
Why You Should Keep An Eye On Delcath Systems - RTTNews
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Biliary Tract Cancer Market Poised for Significant Growth from - openPR
Liver Cancer Treatment Pioneer Delcath Takes Center Stage at Elite Healthcare Summit - StockTitan
Rosalind Advisors, Inc. Expands Stake in Delcath Systems Inc. - GuruFocus.com
retail investors who own 58% along with institutions invested in Delcath Systems, Inc. (NASDAQ:DCTH) saw increase in their holdings value last week - Yahoo Finance
Delcath Systems, Inc. to Host Earnings Call - ACCESS Newswire
Delcath SystemsSuper Growth Projections - MSN
Delcath Systems (NASDAQ:DCTH) Hits New 1-Year HighTime to Buy? - MarketBeat
Barclays PLC Invests $104,000 in Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
Delcath Systems Stock Soars to 52-Week High of $15.7 Amidst Surge - Investing.com India
Sensus leads med-tech stock rebound in 2024, year closes with modest sector gain - BioWorld Online
When (DCTH) Moves Investors should Listen - news.stocktradersdaily.com
Delcath Systems stock soars to 52-week high of $13.34 - MSN
Craig Hallum Raises Delcath Systems (NASDAQ:DCTH) Price Target to $21.00 - Defense World
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 - MarketBeat
Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce - Simply Wall St
Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Down 23.0% in December - Defense World
Delcath Systems stock retains Buy rating as Craig-Hallum raises price target by 17% - MSN
Delcath Systems stock soars to 52-week high of $13.34 By Investing.com - Investing.com Canada
Delcath Systems, Inc. (NASDAQ:DCTH) Sees Large Decrease in Short Interest - MarketBeat
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
2.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):